Founder and CEO, has 15 years of R&D experience in early stage Medtech companies, including R&D roles at Thoratec (acquired by Abbot) and Outset Medical (IPO). He excels at developing and launching paradigm-changing technology, setting up manufacturing processes, managing quality systems, and training physicians. Mr. Hsu holds a B.S. in Mechanical Engineering from the University of California, Berkeley.

Director of Sales, brings over 20 years of experience in the medical device industry. Mr. Lott developed and successfully executed the launch of Rezum in Florida. He specializes in product launch, sales leadership, and team building. He has worked in sales or sales leadership for early-stage companies like Saluda Medical, Axonics, and Mi Medx, and in large Medtech corporations like Medtronic, Dendreon, and Hollister. He has won numerous national sales and sales leadership awards and has mentored and trained countless high-performing sales representatives. Mr. Lott holds a B.S. from Catawba College and an M.B.A. from Gardner-Webb University.

Leads QA, Regulatory, and Clinical, with 33 years of experience helping multiple companies obtain clearances. Ms. Hoy was previously the Executive VP of Regulatory/Quality/Clinical at Cynosure (Hologic), and VP of RA/QA at Cutera, Xoft, and Lumenis. She is a graduate of the University of New Mexico.

Has over 15 years of experience in the medical device industry. She has worked with leaders like Covidien/Medtronic and guided startups in meeting FDA and global standards. Ms. Kaulback has led audits and driven continuous improvement of quality systems, supporting the development of innovative solutions. Ms. Kaulback holds a B.A. in Molecular, Cellular, and Developmental Biology from the University of California, Santa Cruz, and an M.B.A. from Saint Mary’s College of California.

Brings over 30 years of Engineering and Operations experience in the Medtech industry. Before joining Aulea Medical, he served as Vice President of Operations at Spire Health (acquired by Wellinks) where he oversaw domestic and international operations. Prior to that, Mr. Lagasca held Engineering and Operations leadership positions at Nevro Corporation, Invuity Corporation (acquired by Stryker) and Thoratec Corporation (acquired by Abbott), and he served in engineering positions at Target Therapeutics (now Boston Scientific) and Lifescan Inc., a Johnson & Johnson subsidiary. He holds a BS in Electrical Engineering from SanFrancisco State University.

Mr. Esch has 32+ years of experience in board leadership, starting Medtech companies, inventing novel medical devices, and leading R&D and product management teams. He is the Founder, Board Chair, CEO & CFO of Venclose (acquired by Becton Dickinson) for chronic venous insufficiency office-based treatment. Mr. Esch has also held senior leadership roles at Stryker Neurovascular and Covidien (now Medtronic). He holds a B.S. in Mechanical Engineering from the University of California, San Diego, and an M.S. in Materials Science & Engineering from Stanford University.

Ms. Hou  has 25 years of experience investing in innovative technology that makes a difference in the lives of patients. She has held senior leadership roles in the commercial real estate industry, and serves on the board of Interlink Electronics. Ms. Hou holds a B.S. in Hotel Administration from Cornell University.

Mr. Jan is a serial entrepreneur and early-stage investor who brings insights and capital. He is currently Founder & Managing Director at Taiwan Global Angels, an Advisor to startup founders at Berkeley SkyDeck, a Senior Advisor to the Dean of the UC Berkeley School of Public Health, and a Visiting Scholar at UC Berkeley’s Bioengineering and Biomedical Engineering departments. Mr. Jan has a PhD and MS in Biomedical Engineering/EE and a BS in Physics from National Taiwan University, and an MBA from National Chengchi University.

Dr. Dean Elterman is one of Canada’s leading urologists and innovators in BPH and minimally invasive urologic surgery. He is the Lang Family Endowed Chair in Urologic Innovation, Associate Professor of Urology at the University of Toronto, and attending urologist at the University Health Network. Dr. Elterman has published more than 290 peer-reviewed papers, leads numerous clinical trials in BPH and neuromodulation, and authored the European (EAU) and Canadian guidelines for Male LUTS/BPH. He also serves on the Board of Directors of the Société Internationale d’Urologie and is widely recognized for helping introduce and advance many next-generation minimally invasive BPH technologies across Canada and internationally. As Medical Advisor to Aulea Medical, he provides strategic clinical guidance supporting the development of innovative disposable urology platforms.

Dr. Joseph M. Chalil is a seasoned clinical and healthcare leader with more than 26 years of experience across the pharmaceutical, biotechnology, diagnostics, and healthcare sectors. He has held senior leadership roles at major global healthcare companies including Abbott, Hoffmann-La Roche, Boehringer Ingelheim, and DBV Technologies, with deep expertise in clinical strategy, regulatory pathways, clinical trial design, and healthcare innovation. Dr. Chalil advises organizations on U.S. FDA regulatory submissions, CLIA waiver strategies, ISO 13485/MDSAP compliance, and global healthcare expansion, while also serving as an advisor to the Ministry of Health of India and as a U.S. Navy Medical Corps veteran.

Mr. Hamid Ali is an experienced operations and transformation leader with more than 25 years of global experience driving large-scale operational excellence initiatives across healthcare, financial services, manufacturing, and technology sectors. During his 17 years at Genpact, he supported GE Healthcare in executing complex global operations and transformation programs focused on process optimization, efficiency, and strategic execution. Mr. Ali specializes in operational transformation, cross-functional leadership, partnership development, and scaling organizations through structured execution, helping companies align strategy with measurable operational results in complex, fast-moving business environments.

Mr. Michael Mark is a highly experienced healthcare systems executive with more than 40 years of leadership across managed care organizations, healthcare technology, and provider networks. He has served as President and CEO of multiple managed care entities, including Blue Care Network, Health Plus, Methodist Memphis PHO, and DMC Care, overseeing approximately $3.4 billion in annual revenue and more than 3,300 employees. Mr. Mark has extensive expertise in healthcare system operations, payer-provider integration, Medicaid administration, healthcare IT infrastructure, and large-scale healthcare transformation initiatives, including leadership roles supporting Kaiser Permanente Epic EMR implementation programs and strategic initiatives involving CMS, Tricare, and the Military Health System.